Whatever the business model we set up, Just – Evotec Biologics forms strong and mutually beneficial collaborations based on transparency, trust and shared success. Together with our partners we want to accelerate and de-risk development steps, ultimately providing patients with cost-effective biotherapeutics treatments.

Our platform is a perfect fit for discovery and CMC/First-In-Human activities as well as later clinical stages. We can also easily ensure coordination of preclinical/toxicology packages through the global Evotec capabilities if required.

We benefit from the strong expertise of the Evotec group in setting up fully integrated discovery, preclinical and CMC programs for which we ensure superior alliance/project management and bring deep disease knowledge.

At Just -Evotec Biologics, we are also leveraging our advanced end-to-end continuous manufacturing platform to support late clinical phase and commercial pipeline with truly flexible supply chain and lowest COGS manufacturing options.

The combined performance, agility and cost-efficiency of our platform positions Just - Evotec Biologics as a partner of choice for both pandemic preparedness and fast global biotherapeutic drug supply.